🔍 Research any topic with AI-powered citations — Try Researchly freeStart Researching
Home/Research/how do mRNA vaccines work mechanism of action
AI Research Answer

how do mRNA vaccines work mechanism of action

Rahul PalRahul Pal·researched on Researchly·June 18, 2026Try free
ShareWhatsAppShare on X

How mRNA Vaccines Work: Mechanism of Action

╔══════════════════════════════════════════════════════════════════════════════╗ ║ mRNA VACCINE: END-TO-END PIPELINE ║ ╚══════════════════════════════════════════════════════════════════════════════╝

┌─────────────────────────────────────────────────────────┐ │ STEP 1: VACCINE COMPOSITION │ │ │ │ ┌──────────────────────────────────────────────────┐ │ │ │ Lipid Nanoparticle (LNP) │ │ │ │ │ │ │ │ OUTER WALL │ │ │ │ ┌────────────────────────────────────────────┐ │ │ │ │ │ Neutral Helper Lipids (encapsulating) │ │ │ │ │ │ ┌──────────────────────────────────────┐ │ │ │ │ │ │ │ LNP CORE │ │ │ │ │ │ │ │ ● mRNA (modified nucleosides) │ │ │ │ │ │ │ │ ● Ionizable Cationic Lipids │ │ │ │ │ │ │ │ ● Water │ │ │ │ │ │ │ └──────────────────────────────────────┘ │ │ │ │ │ └────────────────────────────────────────────┘ │ │ │ └──────────────────────────────────────────────────┘ │ │ │ │ KEY: mRNA encodes prefusion-stabilized spike protein │ └─────────────────────────────────────────────────────────┘ │ ▼ (injection / route of administration) ┌─────────────────────────────────────────────────────────┐ │ STEP 2: DELIVERY & CELLULAR UPTAKE │ │ │ │ LNP ──► [Endocytosis] ──► Host Cell │ │ │ │ │ LNP core releases mRNA │ │ into cytoplasm │ └─────────────────────────────────────────────────────────┘ │ ▼ ┌─────────────────────────────────────────────────────────┐ │ STEP 3: TRANSLATION (Antigen Production) │ │ │ │ mRNA ──► [Ribosomes] ──► Spike Protein Antigen │ │ (prefusion-stabilized) │ │ │ │ Modified nucleosides (e.g., pseudouridine, │ │ 5-methylcytidine) ──► Suppress TLR activation │ │ ──► Reduce immunogenicity │ │ ──► Preserve translational │ │ capacity │ └─────────────────────────────────────────────────────────┘ │ ┌───────────┴────────────┐ ▼ ▼ ┌────────────────────────┐ ┌─────────────────────────────┐ │ STEP 4A: INNATE │ │ STEP 4B: ANTIGEN │ │ IMMUNE ACTIVATION │ │ PRESENTATION │ │ │ │ │ │ ● Type I Interferon ↑ │ │ Spike Protein displayed │ │ ● Innate immune cells │ │ on cell surface via MHC │ │ primed │ │ │ └────────────────────────┘ └─────────────────────────────┘ │ │ └───────────┬────────────┘ ▼ ┌─────────────────────────────────────────────────────────┐ │ STEP 5: ADAPTIVE IMMUNE RESPONSE (Priming) │ │ │ │ ┌─────────────────────────────────┐ │ │ │ Antigen-Specific Responses │ │ │ │ │ │ │ │ ┌────────────┐ ┌────────────┐ │ │ │ │ │ CD4+ T │ │ CD8+ T │ │ │ │ │ │ Cells │ │ Cells │ │ │ │ │ │ (Helper) │ │ (Cytotoxic)│ │ │ │ │ └─────┬──────┘ └────────────┘ │ │ │ │ │ │ │ │ │ ▼ │ │ │ │ ┌────────────┐ │ │ │ │ │ B Cells │ │ │ │ │ │ ──► │ │ │ │ │ │ Neutraliz. │ │ │ │ │ │ Antibodies │ │ │ │ │ └────────────┘ │ │ │ └─────────────────────────────────┘ │ └─────────────────────────────────────────────────────────┘ │ ▼ ┌─────────────────────────────────────────────────────────┐ │ STEP 6: PROTECTION OUTCOMES │ │ │ │ BNT162b2 (Pfizer): ~95% efficacy vs. COVID-19 │ │ mRNA-1273 (Moderna): ~94.1% efficacy vs. COVID-19 │ │ │ │ Protection against: infection, symptomatic disease, │ │ hospitalization, ICU admission, death │ └─────────────────────────────────────────────────────────┘

Want to research your own topic? Try it free →
mRNA vaccines rely on lipid nanoparticles (LNPs) to carry and protect the mRNA payload. Schoenmaker et al. (2021)1showed that mRNA, the ionizable cationic lipid, and water are present in the LNP core, while the neutral helper lipids are mainly positioned in the outer, encapsulating wall.1
1
mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stabilityLinde Schoenmaker, Dominik Witzigmann et al.2021International Journal of Pharmaceutics
View
A critical stability concern with this platform is that mRNA hydrolysis is the determining factor for mRNA-LNP instability, which is why current COVID-19 vaccines require (ultra)low-temperature storage.1To improve stability,1

found that optimization of the mRNA nucleotide composition should be prioritized.

A foundational challenge for mRNA therapeutics was that in vitro–transcribed (IVT) mRNA activated immune signaling via Toll-like receptors (TLRs), which limited therapeutic mRNA use. Karikó et al. (2005)1demonstrated that incorporation of naturally occurring modified nucleosides — pseudouridine, 5-methylcytidine, 2-thiouridine, and others — into mRNA suppresses TLR activation and dramatically reduces immunogenicity while preserving translational capacity.1This nucleoside modification strategy formed the foundational basis for COVID-19 mRNA vaccines.1
1
Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNAKatalin Karikó, Michael Buckstein et al.2005Immunity
View
Weissman & Karikó (2015)2further confirmed that the immunogenicity problem that had previously prevented IVT mRNA's development for protein replacement therapies was solved by the introduction of modified nucleosides.2
2
mRNA: Fulfilling the Promise of Gene TherapyDrew Weissman, Katalin Karikó2015Molecular Therapy
View
Want to research your own topic? Try it free →

Both leading COVID-19 mRNA vaccines encode a specifically engineered antigen:

  • BNT162b2 encodes a prefusion-stabilized full-length SARS-CoV-2 spike protein using modified mRNA delivered in lipid nanoparticles.
1
  • mRNA-1273 uses lipid nanoparticle-formulated mRNA encoding the prefusion-stabilized spike protein as well.
2
1
Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineFernando P. Polack, Stephen J. Thomas et al.2020New England Journal of Medicine
View
2
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 VaccineLindsey R. Baden, Hana M. El Sahly et al.2021New England Journal of Medicine
View

Corbett et al. (2020) reported that the 2-P stabilizing mutations used in mRNA-1273's immunogen design were derived from prior MERS-CoV spike studies, enabling mRNA-1273 to induce robust neutralizing antibody responses and CD4 and CD8 T cell responses in mice.

Carlo et al. (2017)1described that the mechanism of action of mRNA vaccines encompasses the bio-distribution of mRNA, localization of antigen production, the role of innate immunity, and priming of the adaptive immune response.1
1
Mechanism of action of mRNA-based vaccines.Iavarone Carlo, O'hagan Derek T et al.2017Expert review of vaccines
View
Research in the oncology context adds further granularity: SARS-CoV-2 mRNA vaccines lead to a substantial increase in type I interferon, enabling innate immune cells to prime CD8+ T cells.2Similar correlates of vaccination response, including increases in type I interferon and myeloid-lymphoid activation, have been found in healthy human volunteers.2
2
SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade.Grippin Adam J, Marconi Christiano et al.2025Nature
View
Want to research your own topic? Try it free →

The adaptive immune responses translate into strong clinical efficacy:

  • Polack et al. (2020)
1reported that two doses of BNT162b2 conferred 95% protection against COVID-19 in a Phase 3 trial of 43,548 participants, with the majority of adverse events being mild to moderate and transient.1
  • Baden et al. (2021)
2reported that mRNA-1273 showed 94.1% efficacy at preventing COVID-19 illness in a Phase 3 trial of 30,420 participants, with severe adverse events rare and similar between vaccine and placebo groups.2
1
Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineFernando P. Polack, Stephen J. Thomas et al.2020New England Journal of Medicine
View
2
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 VaccineLindsey R. Baden, Hana M. El Sahly et al.2021New England Journal of Medicine
View

In a head-to-head comparison, Dickerman et al. (2021) found that both BNT162b2 and mRNA-1273 are more than 90% effective against COVID-19, though their comparative effectiveness across diverse outcomes was the subject of that study's direct investigation.

Scope note: The evidence blocks directly support the steps above. Finer mechanistic details (e.g., endosomal escape kinetics, germinal center reactions, memory B-cell formation) are not covered by the retrieved evidence and cannot be stated here.

More research like thisResearch your own
What is BERT and how does it work6 views·25 Mayhow does BERT pre-training work4 views·25 Mayhow does reinforcement learning work reward policy2 views·18 Junneural network training optimization gradient descent2 views·18 JunT5 text-to-text transfer learning unified framework2 views·18 Junhow does semiconservative DNA replication work2 views·18 Jun

Research smarter with AI-powered citations

Researchly finds and cites academic papers for any research topic in seconds. Used by students across India.

Remix this research Start a new researchSee Pricing